Header Logo

Connection

Abde Abukhdeir to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Abde Abukhdeir has written about Drug Administration Schedule.
Abde Abukhdeir
Connection Strength
0.044
Drug Administration Schedule
  1. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021 04 15; 27(8):2126-2129.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.